JP2013526501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013526501A5 JP2013526501A5 JP2013509525A JP2013509525A JP2013526501A5 JP 2013526501 A5 JP2013526501 A5 JP 2013526501A5 JP 2013509525 A JP2013509525 A JP 2013509525A JP 2013509525 A JP2013509525 A JP 2013509525A JP 2013526501 A5 JP2013526501 A5 JP 2013526501A5
- Authority
- JP
- Japan
- Prior art keywords
- cooh
- insulin
- chain
- group
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 20
- 238000000034 method Methods 0.000 claims 14
- 102000004877 Insulin Human genes 0.000 claims 8
- 108090001061 Insulin Proteins 0.000 claims 8
- 229940125396 insulin Drugs 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 239000004026 insulin derivative Substances 0.000 claims 6
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 5
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 4
- 125000002843 carboxylic acid group Chemical group 0.000 claims 4
- 239000011701 zinc Substances 0.000 claims 4
- 229910052725 zinc Inorganic materials 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000004246 zinc acetate Substances 0.000 claims 1
- -1 zinc atoms insulin derivative Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10162368 | 2010-05-10 | ||
| EP10162368.4 | 2010-05-10 | ||
| US33349710P | 2010-05-11 | 2010-05-11 | |
| US61/333,497 | 2010-05-11 | ||
| PCT/EP2011/057388 WO2011141407A1 (en) | 2010-05-10 | 2011-05-09 | Process for the preparation of insulin-zinc complexes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157054A Division JP2017203042A (ja) | 2010-05-10 | 2017-08-16 | インスリン−亜鉛錯体の調製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013526501A JP2013526501A (ja) | 2013-06-24 |
| JP2013526501A5 true JP2013526501A5 (enExample) | 2014-05-08 |
| JP6249773B2 JP6249773B2 (ja) | 2017-12-20 |
Family
ID=42732779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013509525A Active JP6249773B2 (ja) | 2010-05-10 | 2011-05-09 | インスリン−亜鉛錯体の調製方法 |
| JP2017157054A Withdrawn JP2017203042A (ja) | 2010-05-10 | 2017-08-16 | インスリン−亜鉛錯体の調製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157054A Withdrawn JP2017203042A (ja) | 2010-05-10 | 2017-08-16 | インスリン−亜鉛錯体の調製方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20130143803A1 (enExample) |
| EP (1) | EP2569002B1 (enExample) |
| JP (2) | JP6249773B2 (enExample) |
| KR (2) | KR20160105979A (enExample) |
| CN (2) | CN107029212A (enExample) |
| AU (1) | AU2011252127B2 (enExample) |
| BR (1) | BR112012028766A2 (enExample) |
| CA (1) | CA2795091A1 (enExample) |
| ES (1) | ES2612468T3 (enExample) |
| MX (1) | MX2012012943A (enExample) |
| RU (1) | RU2572214C2 (enExample) |
| WO (1) | WO2011141407A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8067362B2 (en) | 2005-02-02 | 2011-11-29 | Novo Nordisk As | Insulin derivatives |
| PT1969004E (pt) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
| WO2007096431A1 (en) | 2006-02-27 | 2007-08-30 | Novo Nordisk A/S | Insulin derivatives |
| EP2386572B1 (en) | 2006-05-09 | 2015-07-08 | Novo Nordisk A/S | Insulin derivative |
| US8796205B2 (en) | 2006-05-09 | 2014-08-05 | Novo Nordisk A/S | Insulin derivative |
| JP5552046B2 (ja) | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | インスリン誘導体を含有する薬学的製剤 |
| EP2217621B1 (en) | 2007-11-08 | 2015-04-22 | Novo Nordisk A/S | Insulin derivative |
| KR20110085985A (ko) | 2008-10-30 | 2011-07-27 | 노보 노르디스크 에이/에스 | 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료 |
| JP6049625B2 (ja) | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー／エス | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 |
| JP6755175B2 (ja) * | 2013-03-20 | 2020-09-16 | ノヴォ ノルディスク アー／エス | インスリン投薬レジメン |
| WO2014177623A1 (en) | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
| WO2015052088A1 (en) * | 2013-10-07 | 2015-04-16 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| DK3006045T3 (en) | 2014-10-07 | 2017-07-17 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
| MX2020005916A (es) | 2017-12-07 | 2020-10-19 | Adocia | Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido. |
| WO2019110797A1 (fr) * | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| CA3090199A1 (en) * | 2018-02-01 | 2019-08-08 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof |
| CA3100869A1 (en) | 2018-05-24 | 2019-11-28 | Jiangsu Hengrui Medicine Co., Ltd. | Method for preparing precursor of recombinant human insulin or analogue thereof |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| SG11202106167XA (en) | 2018-12-11 | 2021-07-29 | Sanofi Sa | Insulin conjugates |
| EP3996679B1 (en) | 2019-07-12 | 2023-09-06 | Novo Nordisk A/S | High concentration insulin formulation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1212679B (de) * | 1957-08-03 | 1966-03-17 | Novo Terapeutisk Labor As | Verfahren zur Herstellung von Insulinloesungen |
| GB1042194A (en) * | 1962-04-30 | 1966-09-14 | Olin Mathieson | Insulin preparations |
| US3868358A (en) * | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
| DK113585D0 (da) * | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| US4764592A (en) * | 1987-04-23 | 1988-08-16 | Eli Lilly And Company | Crystalline human proinsulin and process for its production |
| FI913037A0 (fi) | 1988-12-23 | 1991-06-20 | Novo Nordisk As | Humana insulinanaloger. |
| PT93057B (pt) | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
| EP1132404A3 (en) * | 1993-09-17 | 2002-03-27 | Novo Nordisk A/S | Acylated insulin |
| US7097845B2 (en) * | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| EP2107069B1 (en) | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| ES2402592T3 (es) * | 2003-08-05 | 2013-05-07 | Novo Nordisk A/S | Nuevos derivados de insulina |
| PT1969004E (pt) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
| JP5552046B2 (ja) * | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | インスリン誘導体を含有する薬学的製剤 |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
-
2011
- 2011-05-09 KR KR1020167023293A patent/KR20160105979A/ko not_active Ceased
- 2011-05-09 WO PCT/EP2011/057388 patent/WO2011141407A1/en not_active Ceased
- 2011-05-09 MX MX2012012943A patent/MX2012012943A/es active IP Right Grant
- 2011-05-09 RU RU2012148821/15A patent/RU2572214C2/ru not_active IP Right Cessation
- 2011-05-09 ES ES11718398.8T patent/ES2612468T3/es active Active
- 2011-05-09 KR KR1020127029547A patent/KR20130092972A/ko not_active Ceased
- 2011-05-09 JP JP2013509525A patent/JP6249773B2/ja active Active
- 2011-05-09 CN CN201611166272.4A patent/CN107029212A/zh active Pending
- 2011-05-09 CN CN201180023303XA patent/CN102883743A/zh active Pending
- 2011-05-09 CA CA2795091A patent/CA2795091A1/en not_active Withdrawn
- 2011-05-09 US US13/696,897 patent/US20130143803A1/en not_active Abandoned
- 2011-05-09 AU AU2011252127A patent/AU2011252127B2/en not_active Ceased
- 2011-05-09 EP EP11718398.8A patent/EP2569002B1/en active Active
- 2011-05-09 BR BR112012028766A patent/BR112012028766A2/pt not_active Application Discontinuation
-
2015
- 2015-03-19 US US14/662,874 patent/US20150250857A1/en not_active Abandoned
-
2017
- 2017-02-28 US US15/445,305 patent/US20170165327A1/en not_active Abandoned
- 2017-08-16 JP JP2017157054A patent/JP2017203042A/ja not_active Withdrawn
-
2020
- 2020-08-12 US US16/991,803 patent/US20210060132A1/en not_active Abandoned
-
2024
- 2024-05-24 US US18/674,042 patent/US20240307503A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013526501A5 (enExample) | ||
| JP2011006428A5 (enExample) | ||
| RU2012148821A (ru) | Способ получения цинковых комплексов инсулина | |
| EP3494961A1 (en) | Compositions and methods for treating chronic inflammation and inflammatory diseases | |
| RU2015100901A (ru) | Производные эфира гетероарилкарбоновой кислоты | |
| JP2013523896A5 (enExample) | ||
| WO2012165915A3 (en) | Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate | |
| TW200418906A (en) | High-molecular weight derivatives of camptothecins | |
| TW200914460A (en) | Proteasome inhibitors | |
| WO2013104861A1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue | |
| JP2011516428A5 (enExample) | ||
| AU2007274402A1 (en) | Polymer conjugate of combretastatin | |
| CA3084688A1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes | |
| CA2846598C (en) | Treatment of degenerative joint disease | |
| WO2011015634A3 (en) | Controlled release formulations of lipocalin muteins | |
| WO2011018635A3 (en) | Photosensitizing compositions | |
| JP2023540149A (ja) | 抗ウイルス化合物の製剤 | |
| RU2014109441A (ru) | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами | |
| Gandhi et al. | Carriers for prodrug synthesis: A review | |
| WO2006131923A3 (en) | Novel salts of conjugated psychotropic drugs and processes of preparing same | |
| CA2565993A1 (en) | Salt of 4-or 5- aminosalicylic acid | |
| JP2014500244A5 (enExample) | ||
| WO2020025825A1 (fr) | Solution injectable a ph 7 comprenant du glucagon humain, au moins une espece ionique et un compose amphiphile porteur de radicaux hydrophobes | |
| EP3829624A1 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline, au moins une espece ionique et un compose amphiphile porteur de radicaux hydrophobes | |
| WO2012165916A3 (en) | Non-peptidyl polymer-insulin multimer and method for producing the same |